Background Cognitive impairment is a widespread feature of schizophrenia, affecting nearly
80% of patients. Prior research has linked the anticholinergic burden of psychiatric …

Objective: Many psychotropic medications used to treat schizophrenia have significant
anticholinergic properties, which are linked to cognitive impairment and dementia risk in …

Aim The anticholinergic properties of medications are associated with poorer cognitive
performance in schizophrenia. Numerous scales have been developed to assess …

Background Cognitive deficits are prevalent in people with schizophrenia and associated
with functional impairments. In addition to antipsychotics, pharmacotherapy in schizophrenia …

Objective This study aimed to explore the association between medication-associated
anticholinergic burden and cognitive and daily living functions in patients with …

Objective: Cognitive impairment in schizophrenia forms the key cause of the disease's
disability, leading to serious functional, and socioeconomic implications. Dopaminergic …

Background Patients with psychotic disorders are often treated with numerous medications,
many of which have anticholinergic activity. We assessed cognition in relation to the …

Background Patients with psychosis frequently use a variety of psychotropic medicines,
many of which have anticholinergic effects that can impair cognition. Therefore, this study …

Anticholinergic burden (ACB) from medications impairs cognition in schizophrenia.
Cognition is a predictor of functional capacity; however, little is known about ACB effect on …

Objective: Schizophrenia is treated with medications that raise serum anticholinergic activity
and are known to adversely affect cognition. The authors examined the relationship between …